AstraZeneca H1 2026 Results: Total Revenue Climbs to $30.7 Billion as Company Reaffirms $80 Billion 2030 Ambition
AstraZeneca’s H1 2026 results show Total Revenue climbing 9% to $30,672 million and Core EPS up 12% to $5.21, powered by Oncology and Rare Disease growth, 30 new regulatory approvals, and fresh licensing deals for Zegfrovy and TQC3721 — as the company reaffirms its $80 billion 2030 revenue ambition.
